Biotica Technology Limited

Isomerase Therapeutics, Ltd.

Neurovive Pharmaceutical Ab

Abliva Ab

Steven Gary Kendrew

Steven James Moss

Matthew Alan Gregory

Barrie Wilkinson

Peter Francis Leadlay

Christine Janet Martin

Hrvoje Petkovic

Rachel E Lill

A method for increasing the molecular diversity of polyketides and non-ribosomal peptides by using recombination to efficiently increase or decrease the number of modules in the polyketide synthase or non-ribosomal peptide synthetase encoding the polyketide or peptide.

Methods for increasing molecular diversity of polyketides and non-ribosomal proteins

Novel rapamycin analogues and methods for their production with FKBP and/or MIP inhibitory activity with reduced mTOR inhibitory activity with therapeutic potential e.g. as bacterial virulence inhibitors.

Rapamycin analogues and their pharmaceutical use

There are provided inter alia compounds of formula (I) and (II) and their use in therapy, particularly for the treatment of viral infection.

Sanglifehrin derivatives and methods for their production

14-membered macrolide compounds such as erythromycins are provided with functional groups at the 14- and/or 15-position by providing a 14-membered aglycone template and feeding it to a strain capable of hydroxylating it at the 14 and/or 15 position. The strain may be found by screening, selected from known strains (e.g.DSM 40014) or produced by genetically engineering a strain to express a cytochrome P450 enzyme.

Erythromycins and process for their preparation

Biosyntheses of compounds whereof at least portions are polyketides produced by means of polyketide synthase (PKS) enzyme complexes are carried out after specific alterations have been made within the acyltransferase (AT) domains of the PKSs. Particular motifs in or near the substrate binding pocket are disclosed, such that alterations therein affect substrate specificity.

Growing community of inventors

Cambridge, United Kingdom

Steven Gary Kendrew